Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
Location: Central Cambridge The Department of Pharmacology at the University of Cambridge, in partnership with AstraZeneca, is offering a funded PhD studentship to study proteasome-targeting tools
-
Applications are invited for an AstraZeneca Non-Clinical PhD Studentship in Development of an Integrated Pre-Clinical Pipeline for Safety Assessment of Small Molecule and Peptide-Based
-
Applications are invited for 4-year PhD studentship based in Cambridge Institute of Medical Research (CIMR), University of Cambridge and the new AstraZeneca Discovery Centre at Cambridge
-
collaboration between AstraZeneca and Queen Mary University of London (QMUL). A Knowledge Transfer Partnership (KTP) is a collaborative program encouraging innovation by connecting businesses and universities, co
-
collaboration between AstraZeneca and Queen Mary University of London (QMUL). A Knowledge Transfer Partnership (KTP) is a collaborative program encouraging innovation by connecting businesses and universities, co
-
Associate in collaboration between AstraZeneca and Queen Mary University of London (QMUL) within the domain of Artificial Intelligence for multimodal integration of multi-omics and imaging data. About the
-
thriving PhD and research programs. The Department of Biology has 25 full-time faculty members, over 750 undergraduate majors, and approximately 60 graduate students enrolled in Ph.D. and M.S. programs
-
well as with advice from leading pharmaceutical companies such as AstraZeneca. The collaboration with industry, universities and research infrastructures ensures access to cutting-edge expertise and advanced
-
companies such as AstraZeneca. The collaboration with industry, universities, and research infrastructures ensures access to cutting-edge expertise and advanced research resources. The project includes two
-
clinical trials. The group is led by Professor Teresa Lambe OBE, a Principal Investigator on the Oxford/AstraZeneca COVID‑19 vaccine programme, who co‑designed the vaccine in January 2020, led pre‑clinical